These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28029447)

  • 1. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
    McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
    Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
    Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
    Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
    De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
    J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.
    Dizon DS; Blessing JA; McMeekin DS; Sharma SK; Disilvestro P; Alvarez RD
    J Clin Oncol; 2009 Jul; 27(19):3104-8. PubMed ID: 19451430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
    Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
    Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
    Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
    Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Miller DS; Blessing JA; Schilder J; Munkarah A; Lee YC
    Gynecol Oncol; 2005 Aug; 98(2):217-21. PubMed ID: 15975641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
    Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
    Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Campos SM; Brady WE; Moxley KM; O'Cearbhaill RE; Lee PS; DiSilvestro PA; Rotmensch J; Rose PG; Thaker PH; O'Malley DM; Hanjani P; Zuna RE; Hensley ML
    Gynecol Oncol; 2014 Jun; 133(3):537-41. PubMed ID: 24594074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
    Takano T; Otsuki T; Tokunaga H; Toyoshima M; Utsunomiya H; Nagase S; Niikura H; Ito K; Yaegashi N; Yamada H; Tase T; Kagabu M; Shoji T; Sugiyama T; Sato N; Fujimoto T; Terada Y; Nakahara K; Kurachi H; Yokoyama Y; Mizunuma H; Soeda S; Nishiyama H; Matsumoto T; Sato S; Shimada M; Kigawa J
    Int J Clin Oncol; 2014 Dec; 19(6):1052-8. PubMed ID: 24395448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
    Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
    Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Darcy KM; Abulafia O; Hanjani P; Pearl ML; Rubin SC; Rose PG; Small L; Benbrook DM
    Gynecol Oncol; 2012 Nov; 127(2):356-61. PubMed ID: 22796461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
    Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
    J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
    Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
    J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.